Early detection of cancer can enhance the survival rate of patients but the success strongly relies on the availability of specific and sensitive biomarkers. One class of promising biomarkers for cancer diagnosis is the microRNAs (miRNAs). They bind to target mRNAs and inhibit translation or induce degradation of target transcripts. 1, 2 Overexpression of miRNAs that inhibit the tumor suppressor genes can interfere with the anti-oncogenic pathway; while deletion or epigenetic silencing of miRNAs that target oncogenes can increase oncogenic potency. [3] [4] [5] [6] It is also recognized that miRNA profiles more accurately reflect the developmental lineage and tissue origin of human cancers than the mRNA profiles. [7] [8] [9] Compared to proteins, miRNAs have simpler structure and less complex post-synthesis processing; and can be detected by the highly sensitive PCR methods. More appealing, miRNAs can be released into the circulation system and stably present at levels detectible by sensitive techniques like RT-PCR. [10] [11] [12] [13] Accumulating evidence shows that circulating miRNAs exhibit varied patterns between cancer patients and healthy controls, with the patterns of some secretory miRNAs altered in the early stage of cancer initiation. [14] [15] [16] Since sampling from circulating body fluids, like blood, urine, saliva, etc. is considered to be convenient and non-invasive compared to other biopsy methods, more and more research efforts have been devoted to obtaining the comprehensive profiles of circulating miRNAs, and validate their utility as biomarkers. 17, 18 Still, it is a long route from proof-of-principle to creation of reliable and reproducible miRNA clinical tests. One obstacle is that, not all circulating miRNAs are related to cancer development. The cancer-irrelevant miRNAs can be secreted by blood cells; or be shed after cells die. They could then contribute to large variances in miRNA abundances between individuals and subsidize signals from the cancer-related miRNAs during quantification. It has been known that, the cell-free miRNAs are protected from nucleases in extracellular environments and in body fluids by various types of carriers. The carriers can be proteins like Argonaute (AGO) 2 and GW182 19, 20 that belong to the RNA-induced silencing complex (RISC);
be the high-density lipoprotein (HDL) particles that could mediate intracellular communication; 21, 22 or be vesicles like the exosomes [23] [24] [25] which are believed to be one of the exportation routes for miRNAs from malignant cells. 26 While active miRNA secretion by malignant cells could be the consequence of dysregulation of cellular pathways, for-purpose exportation and uptake could be related to tumor progression and metastasis. [27] [28] [29] Therefore, to better eliminate the cancer-irrelevant miRNAs and reveal the more specific miRNA markers, isolation of miRNAs from carriers that are specifically secreted by cancer cells could be a solution. Thus, HDL and exosomes have recently been focused in study of circulating miRNAs.
Pure HDL or exosomes are often obtained by ultracentrifugation 20, 21, 26, [30] [31] [32] and immunoaffinity capture. 33, 34 Ultracentrifugation can provide good size/density resolution; but it requires large sample volumes, is very tedious and time-consuming, and typically renders low recovery. Immunoaffinity capture is easy to perform and provides high specificity, but can only target one type of carriers at a time. 35, 36 In the pioneering study of miRNA carriers done by Arroyo et al., 19 serum was fractionated with size exclusion chromatography (SEC) to reveal the existence of the exosomal and exosome-free circulating miRNAs. Vickers et al. also applied SEC to further characterize the HDL isolated by ultracentrifugation. 21 However, in SEC, good separation resolution can only be achieved within a small size range; interaction of biomolecules with the column materials is problematic; and integrity of biocomplexes or vesicle structures after passing through the packed column is questionable.
While recovering miRNAs from either pure HDL or exosomes could possibly remove the cancer-irrelevant miRNAs shredded by normal cells, it is actually not conclusive about which carriers are more important in cancer diagnosis. Thus, study of miRNA distribution among all types of carriers is necessary to answer this question. Compared to SEC and ultracentrifugation, asymmetrical flow field-flow fractionation (AF4) is gentler for better preservation of the binding between miRNAs and their carriers. 37 Due to its non-interactive separation ability, AF4 can be used to isolate intact macromolecular complexes, such as aptamer-protein interactions, antibodyantigen interactions, and protein-drug interactions. [38] [39] [40] In addition, AF4 has previously been used for analysis of exosomes in serum. [41] [42] [43] Therefore, it is the method of choice for rapid separation of different miRNA carriers based on their hydrodynamic diameters, enabling the screening of miRNA distribution among various carriers. Comparing the distribution profiles obtained from healthy individuals and cancer patients may help to reveal which types of carriers are more relevant to cancer development, and thus enhance the sensitivity and specificity in diagnosis when using the miRNAs enclosed in those carriers as the markers.
Herein, we employed AF4 to fractionate the whole serum. Discrete elution fractions were collected. Total RNAs were extracted from each fraction; and the amounts of 8 selected miRNAs in each fraction were quantified by RT-qPCR. Proteins eluted in each fraction were also extracted and identified to reveal the identities of carriers enriched in each fraction. The distribution profiles acquired from the sera of healthy individuals were compared with those from patients with breast cancer. The purpose was to see whether the miRNA quantities found in particular types of carriers were more useful in differentiating cancer patients from healthy individuals than the overall quantity recovered from serum. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Chemicals and biomaterials. Chemicals used in this study were listed in the Supporting
Materials and Methods
Information. HDL and low-density lipoprotein (LDL) were purchased from CalBioChem (EMD Millipore, Billerica, MA). Trizol LS reagent, 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) and Total Exosome Isolation kit were purchased from Invitrogen (Life Technologies).
MicroRNA standards were purchased from Integrated DNA Technologies (Coralville, IA).
TaqMan MicroRNA Assays specific to each miRNA strand were purchased from Applied Biosystems (Life Technologies). followed by a fraction collector (Bio-Rad). The running buffer for all samples was the 1×PBS mentioned above. During serum fractionation, an initial focusing step of eight minutes was used, with the cross flow (the flow exiting the channel through the membrane wall) at 3.00 mL/min, tip flow (the flow entering the channel from the inlet) at 0.30 mL/min, and focus flow (a flow entering at a position further down from the inlet to focus the analyte into a narrow sample zone) at 3.00 mL/min. After focusing, there was a 1 minute transition period where the tip flow increased to 3.30 mL/min and the focus flow was reduced to zero. Afterwards, the tip flow was kept at 3.30 mL/min for five minutes, and was then reduced to 0.30 mL/min over the course of 15 minutes. In each case, the cross flow was reduced to keep the detector flow (the flow exiting the channel from the outlet) at 0.30 mL/min. A fraction collector (Bio-rad) was used to perform step-wise collection at every minute interval. These 1-min collections for each sample were then combined into 6 fractions, with fraction #1 (F1) containing the eluents collected from 6 to 9 min, extraction was used as an internal standard to correct for sample loss during extraction, and the absolute miRNA quantity in each sample was obtained using an external standard calibration curve prepared from reactions with standard miRNAs. Details of the RT-qPCR reaction conditions can be found in the Supporting Information. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 was achieved if the cross flow gradually decreased to zero within 15 minutes ( The whole human serum purchased from Sigma was fractionated by the optimized AF4 method. We also spiked pure HDL and LDL to the serum for determination of their exact elution windows (Figure 1a) . HDL was eluted within 10-15 min and LDL between 17 and 23 min.
Results and Discussion

AF4
Moreover, we stained the serum or the exosome extracts with the lipophilic dye of DiO prior to AF4 fractionation. DiO is weakly fluorescent in water, but emits strong fluorescence with high photo-stability when incorporated into lipid membranes. The fractograms obtained with fluorescence detection (λ ex = 490 nm; λ em at 510 nm) further confirmed that, structures with lipid membranes were mainly eluted after 17 minutes (Fig. 1b) .
Fractionation of patient serum and confirmation of carriers eluted in each fraction.
Once the approximate windows for elution of the known miRNA carriers were known, we fractionated sera samples collected from 2 healthy females (control, referred as Control #1 and #2) and 2 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 breast cancer (BC) patients (case, Case #1 and #2) (Figure 2) . Six fractions were collected to increase the purity of miRNA carriers enriched in each fraction. The collection window for each fraction was determined by the relative elution times of HDL, LDL, and exosomes obtained from the above study (inset table in Fig. 2 ). Separation was highly reproducible: relative standard deviation (RSD) of the elution time of the peak within each fraction was < 8% using all 8 fractograms collected (four serum samples, each with two repeats) (Supporting Information, This can ensure that the difference detected in miRNA distribution profiles was originated from the presence of BC but not from difference in carrier abundance. Moreover, the high reproducibility greatly simplified the after-column collection: a fraction collector was programmed to automatically collect the eluent every one minute, and the fractions within the desired time windows were combined for subsequent miRNA and protein extraction.
To confirm the identities of carriers enriched in each fraction, proteins eluted in F1-F6
were collected, digested by trypsin, and analyzed by LC-MS/MS. The relative abundance of the eluted proteins were evaluated by spectral counting, [44] [45] [46] which counts the number of mass spectra collected for a specific protein. The percentage of the spectra number for a particular protein among all spectra identified in one sample should be semi-quantitatively proportional to its relative abundance in the mixture. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 among the carriers. Higher resolution will indeed enhance the accuracy in distribution profiling, and can be achieved by injecting lower amounts serum in each round of the separation, but multiple collections will be needed, increasing the overall labor in the analysis, which is not a favorable choice. Increasing the separation force by using a higher crossflow may also be beneficial to separation resolution, but we take the risk of losing more miRNAs due to membrane adsorption. Thus, we used the current fractionation conditions for the present work. Our results, as would be seen in the following discussion, showed that the coarse distribution profiles were adequate in differentiating the cancer patients from healthy controls, as well as in revealing strands and particular carriers that were important to the differentiation.
Distribution of miRNAs in serum.
The total RNAs were precipitated and reconstituted in water for quantification by RT-PCR. As stated above, sera from two groups of donors (all females) were tested. The sera from healthy individuals (Control #1 and #2); and those from breast cancer patients (Case #1 and #2) were analyzed, each with two repeated measurements.
Eight miRNAs were quantified by RT-qPCR. Their sequences are listed in Table S1 , together with the rationale of their inclusion in our study.
Recovery of miRNAs in our method was evaluated by quantification of miR-16 in the
Sigma serum. The total content of miR-16 directly extracted from the whole 20-µL serum by the TRIzol reagent was compared with the sum miRNA quantity recovered from all AF4 fractions obtained with the injection of the same serum volume. A recovery as high as 98% was achieved (Supporting Information, Figure S5 ), indicating no significant loss of miRNAs due to membrane adsorption inside the AF4 channel. The resulted copy number of each miRNA tested in 20-µL serum normally ranged from 10E4 to 10E10. miR-375 and -122 were present at much lower abundances than other strands or even not detected in some of the fractions. The high reproducibility in the separation step and careful processing in miRNA extraction and quantification ensured high analytical reproducibility: the RSD for the Log value of the total miRNA content in the two repeated measurements was < 5% for most of the strands, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 We compared the miRNA copy number found in each fraction between the control and BC samples. Figure 4b shows the Log ratio of the averaged miRNA copy number in the BC samples over that in the control samples; i.e. Log (BC/control), for each miRNA. If the miRNA level was lower in the BC cases than in the controls, a negative Log(ratio) value would be obtained, and vice versa. Larger absolute values of Log (Case/Control) indicate more obvious difference between these two groups. We also included the Log(Case/Control) obtained using the total miRNA quantity from all fractions (displayed as red bars). The sum was to represent the result attainable with the standard approaches in miRNA study, in which the overall expression level of each miRNA is quantified. Fig. 4b clearly showed that, larger differences between the BC and control samples was observed in some fractions than in the sum value for all miRNAs tested, except for miR-155 and -191. This result hints that the miRNA quantity change in some of the carriers could be more sensitive in differentiating the cancer patients from healthy controls than the overall quantity in the whole serum. This speculation was actually supported by the following statistical analysis.
Statistical analysis of the miRNA distribution profiles. To see whether the distribution profile could tell the difference between healthy donors and BC patients, and whether more reliable miRNA biomarkers can be found, for the 8 miRNAs listed in Table S1 , we fitted their 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 miR-16-F5, miR-16-F6, 17-F4, 375-F4, and 122-F4, respectively, can potentially separate healthy donors from BC patients, as shown in the scores plot in Figure 4c . In fact, the first principle component already accounts for 87.1% total variation. Certainly, a sample set containing a much larger number of both healthy controls and cancer patients should be analyzed to draw affirmative conclusion about the capability of these potential markers in cancer diagnosis.
Conclusions
In this research, AF4 was used to rapidly and reproducibly separate serum into fractions, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Supporting Information. Methods used for separation of standard proteins and particles, for protein identification by LC-MS/MS, for the process of RT-qPCR, and for the ELISA procedure in detection of CD-63 in fractions were included; the sequences and information of the selected miRNA strands used in this study were shown in Table S1 ; Fig. S1 contained the fractograms of exosome extract obtained during method optimization, and those for protein and carrier standards analysis were displayed in Fig. S2 ; fractograms for serum fractionation with or without a constant flow region at the beginning can be found Fig. S3 ; Fig. S4 
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